Sarepta readies FDA pitch after a small study spotlights 1% dystrophin add for golodirsen in Duchenne MD

Sarepta readies FDA pitch after a small study spotlights 1% dystrophin add for golodirsen in Duchenne MD

Submitted by admin on September 6, 2017 - 9:52am
Source: 
Endpoints
News Tags: 
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
golodirsen
Headline: 
Sarepta readies FDA pitch after a small study spotlights 1% dystrophin add for golodirsen in Duchenne MD

Do Not Allow Advertisers to Use My Personal information